Deuterated mitragynine
Deuterated mitragynine is an atypical μ-opioid receptor agonist and deuterated analogue of mitragynine which is under development for the treatment of acute pain and opioid-related disorders. It is taken by mouth. Deumitragynine is said to have analgesic effects. The drug is being developed by ATAI Life Sciences and Kures. As of December 2022, it is in phase 1 clinical trials for acute pain and opioid-related disorders.